3.4 Acute Myeloid Leukemia (AML) & Lineage Assignment

Acute Myeloid Leukemia (AML) & Lineage Assignment

Acute Myeloid Leukemia (AML) is a rapid and aggressive hematologic malignancy characterized by the clonal proliferation of immature myeloid precursors (myeloblasts) in the bone marrow and peripheral blood. A critical threshold for the diagnosis of AML is the presence of ≥20% blasts in the bone marrow or blood (with certain exceptions for specific recurrent genetic abnormalities). Flow cytometry provides rapid enumeration of blasts and, crucially, establishes their myeloid lineage, distinguishing AML from Acute Lymphoblastic Leukemia (ALL).

Defining the Myeloblast

In a CD45 vs SSC plot, blasts fall into the "blast gate"—a region of dim CD45 expression and low side scatter. Myeloblasts often have slightly higher SSC than lymphoblasts due to early granule formation.

To classify these blasts as myeloid, a specific panel of antibodies is applied. According to WHO/EGIL criteria, assigning a myeloid lineage requires the expression of at least two myeloid-associated antigens.

Key markers used in AML diagnosis include:

• CD34: A marker of immature hematopoietic stem/progenitor cells. Commonly expressed on myeloblasts but can be absent in certain AML subtypes.
• CD117 (c-kit): A stem cell factor receptor that is highly associated with myeloid differentiation. It is frequently positive in AML and helps distinguish myeloblasts from lymphoblasts.
• HLA-DR: An MHC class II antigen expressed on progenitor cells and mature monocytic/B-cells. Often positive on myeloblasts.
• CD13 and CD33: Pan-myeloid surface markers. They are frequently co-expressed on myeloblasts. CD33 is also a target for directed therapies (e.g., gemtuzumab ozogamicin).
• Myeloperoxidase (MPO): A cytoplasmic enzyme that is the gold standard for proving myeloid differentiation. If a blast population is unequivocally positive for cytoplasmic MPO, the diagnosis is AML, regardless of the expression of other markers (even aberrant lymphoid markers).
• CD64 and CD14: Markers indicating monocytic differentiation.
• CD11b and CD15: Markers indicating maturation toward granulocytes.
• CD41, CD42b, CD61: Markers defining megakaryoblastic differentiation (Acute Megakaryoblastic Leukemia).
• CD71 and Glycophorin A (CD235a): Markers defining pure erythroid leukemia.

Acute Promyelocytic Leukemia (APL)

A critical, medical emergency subtype of AML is Acute Promyelocytic Leukemia (APL), driven by the t(15;17)(q24;q21) translocation resulting in the PML-RARA fusion gene. Patients with APL are at extreme risk of life-threatening coagulopathy (DIC) upon presentation. Flow cytometry plays a vital role in rapidly identifying APL so that specific, life-saving therapy (All-trans retinoic acid, ATRA) can be initiated immediately, even before cytogenetic confirmation.

The classic APL (hypergranular variant) immunophenotype is highly distinctive:

• CD34: Negative (-) (or very dimly positive in a small subset). Normal myeloblasts are usually CD34+.
• HLA-DR: Negative (-). Normal myeloblasts are usually HLA-DR+.
• CD117: Positive (+).
• CD13 and CD33: Brightly Positive (++). CD33 is characteristically uniform and bright.
• MPO: Brightly Positive (++).
• SSC: High (due to heavy granulation).
• CD64: Often brightly positive, while CD11b and CD15 (mature granulocytic markers) are negative, reflecting a differentiation block at the promyelocyte stage.
• CD9: Frequently positive.

The combination of CD34 negative, HLA-DR negative, bright CD33, and bright MPO strongly suggests APL. A microgranular variant exists, which may have lower SSC and occasionally express CD34 or CD2, but still lacks HLA-DR.

Aberrant Antigen Expression in AML

Myeloblasts frequently display aberrant antigen expression (leukemia-associated immunophenotypes, LAIPs).

• Asynchronous expression: Expression of mature markers (like CD15) on CD34+ blasts.
• Cross-lineage expression: Expression of lymphoid markers on myeloblasts. The most common are CD7 (a T-cell marker) and CD56 (an NK-cell marker). CD56 expression in AML is often associated with a poorer prognosis. Less commonly, blasts may express CD19 or CD2.
• Absence of normal antigens: Lack of CD13 or CD33 on early myeloid precursors.

Identifying these LAIPs at diagnosis is critical for tracking Minimal/Measurable Residual Disease (MRD) during follow-up, as these aberrant signatures allow flow cytometrists to distinguish leukemic blasts from normal regenerating myeloblasts in the bone marrow post-chemotherapy.

General Quality Control and Instrument Optimization in Flow Cytometry

Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Quality control (QC) is fundamentally critical to the daily operation of a clinical flow cytometry laboratory. Ensuring that the instrument is performing optimally before analyzing patient samples guarantees that the data generated is accurate, reproducible, and clinically actionable. The basic components of flow cytometry QC include fluidics checks, optics alignment, and electronics calibration, all of which must be monitored continuously to maintain data integrity. Daily QC protocols typically begin with the evaluation of standard calibration beads, which allow the operator to assess laser alignment, verify the stability of optical paths, and measure the consistency of fluidic flow rates. These beads are manufactured to exhibit uniform and precise fluorescent intensities across all measured channels. By analyzing these standard particles, the laboratory can record target values, monitor coefficients of variation (CVs), and track long-term performance using Levey-Jennings charts. Tracking CVs is crucial because any unexplained increase in the variability of a bead's signal usually indicates an underlying problem with the fluidic stream or partial obstruction in the flow cell, which can drastically reduce resolution. Daily QC protocols typically begin with the evaluation of standard calibration beads, which allow the operator to assess laser alignment, verify the stability of optical paths, and measure the consistency of fluidic flow rates. These beads are manufactured to exhibit uniform and precise fluorescent intensities across all measured channels. By analyzing these standard particles, the laboratory can record target values, monitor coefficients of variation (CVs), and track long-term performance using Levey-Jennings charts. Tracking CVs is crucial because any unexplained increase in the variability of a bead's signal usually indicates an underlying problem with the fluidic stream or partial obstruction in the flow cell, which can drastically reduce resolution. Daily QC protocols typically begin with the evaluation of standard calibration beads, which allow the operator to assess laser alignment, verify the stability of optical paths, and measure the consistency of fluidic flow rates. These beads are manufactured to exhibit uniform and precise fluorescent intensities across all measured channels. By analyzing these standard particles, the laboratory can record target values, monitor coefficients of variation (CVs), and track long-term performance using Levey-Jennings charts. Tracking CVs is crucial because any unexplained increase in the variability of a bead's signal usually indicates an underlying problem with the fluidic stream or partial obstruction in the flow cell, which can drastically reduce resolution. Daily QC protocols typically begin with the evaluation of standard calibration beads, which allow the operator to assess laser alignment, verify the stability of optical paths, and measure the consistency of fluidic flow rates. These beads are manufactured to exhibit uniform and precise fluorescent intensities across all measured channels. By analyzing these standard particles, the laboratory can record target values, monitor coefficients of variation (CVs), and track long-term performance using Levey-Jennings charts. Tracking CVs is crucial because any unexplained increase in the variability of a bead's signal usually indicates an underlying problem with the fluidic stream or partial obstruction in the flow cell, which can drastically reduce resolution. Daily QC protocols typically begin with the evaluation of standard calibration beads, which allow the operator to assess laser alignment, verify the stability of optical paths, and measure the consistency of fluidic flow rates. These beads are manufactured to exhibit uniform and precise fluorescent intensities across all measured channels. By analyzing these standard particles, the laboratory can record target values, monitor coefficients of variation (CVs), and track long-term performance using Levey-Jennings charts. Tracking CVs is crucial because any unexplained increase in the variability of a bead's signal usually indicates an underlying problem with the fluidic stream or partial obstruction in the flow cell, which can drastically reduce resolution. Compensation matrices must also be reviewed and updated regularly, particularly in complex multi-color panels used in clinical diagnostic immunophenotyping. Compensation matrices must also be reviewed and updated regularly, particularly in complex multi-color panels used in clinical diagnostic immunophenotyping. Compensation matrices must also be reviewed and updated regularly, particularly in complex multi-color panels used in clinical diagnostic immunophenotyping. Compensation matrices must also be reviewed and updated regularly, particularly in complex multi-color panels used in clinical diagnostic immunophenotyping. Compensation matrices must also be reviewed and updated regularly, particularly in complex multi-color panels used in clinical diagnostic immunophenotyping.